Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

50 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Three linked nomograms for predicting biochemical failure in prostate cancer treated with radiotherapy plus androgen deprivation therapy.
López-Torrecilla J, Boladeras A, Cabeza MA, Zapatero A, Jove J, Esteban LM, Henriquez I, Casaña M, González-San Segundo C, Gómez-Caamaño A, Mengual JL, Hervás A, Muñoz JL, Sanz G. López-Torrecilla J, et al. Among authors: henriquez i. Strahlenther Onkol. 2015 Oct;191(10):792-800. doi: 10.1007/s00066-015-0866-7. Epub 2015 Jul 9. Strahlenther Onkol. 2015. PMID: 26156249
The number of risk factors is the strongest predictor of prostate cancer mortality: multi-institutional outcomes of an extreme-risk prostate cancer cohort.
Gomez-Iturriaga A, Cabeza Á, Pastor J, Jove J, Casaña M, Caamaño AG, Mengual J, Henríquez I, Muñoz J, Hervás A, Segundo CG. Gomez-Iturriaga A, et al. Among authors: henriquez i. Clin Transl Oncol. 2016 Oct;18(10):1026-33. doi: 10.1007/s12094-016-1481-5. Epub 2016 Jan 19. Clin Transl Oncol. 2016. PMID: 26781470
Intermittent versus continuous androgen deprivation therapy to biochemical recurrence after external beam radiotherapy: a phase 3 GICOR study.
Casas F, Henríquez I, Bejar A, Maldonado X, Alvarez A, González-Sansegundo C, Boladeras A, Ferrer F, Hervás A, Herruzo I, Caro M, Rodriguez I, Ferrer C. Casas F, et al. Among authors: henriquez i. Clin Transl Oncol. 2017 Mar;19(3):373-378. doi: 10.1007/s12094-016-1538-5. Epub 2016 Oct 21. Clin Transl Oncol. 2017. PMID: 27770397 Clinical Trial.
Consensus statement on definition, diagnosis, and management of high-risk prostate cancer patients on behalf of the Spanish Groups of Uro-Oncology Societies URONCOR, GUO, and SOGUG.
Henríquez I, Rodríguez-Antolín A, Cassinello J, Gonzalez San Segundo C, Unda M, Gallardo E, López-Torrecilla J, Juarez A, Arranz J. Henríquez I, et al. Clin Transl Oncol. 2018 Mar;20(3):392-401. doi: 10.1007/s12094-017-1726-y. Epub 2017 Aug 7. Clin Transl Oncol. 2018. PMID: 28785912
Importance of 68Ga-PSMA PET/CT in hospital practice. View of the radiation oncologist.
Couñago F, Artigas C, Sancho G, Gómez-Iturriaga A, Gómez-Caamaño A, Maldonado A, Caballero B, López-Campos F, Recio M, Del Cerro E, Henríquez I. Couñago F, et al. Among authors: henriquez i. Rev Esp Med Nucl Imagen Mol (Engl Ed). 2018 Sep-Oct;37(5):302-314. doi: 10.1016/j.remn.2018.07.005. Epub 2018 Aug 20. Rev Esp Med Nucl Imagen Mol (Engl Ed). 2018. PMID: 30139594 Review. English, Spanish.
Consensus on management of castration-resistant prostate cancer on behalf of the Urological Tumours Working Group (URONCOR) of the Spanish Society of Radiation Oncology.
Gómez-Caamaño A, González-San Segundo C, Henríquez I, Maldonado X, Zapatero A; Expert Panel for the Consensus on Management of Castration-Resistant Prostate Cancer 2017, Urological Tumours Working Group (URONCOR), Spanish Society of Radiation Oncology (SEOR). Gómez-Caamaño A, et al. Among authors: henriquez i. Clin Transl Oncol. 2019 Apr;21(4):420-432. doi: 10.1007/s12094-018-1940-2. Epub 2018 Oct 6. Clin Transl Oncol. 2019. PMID: 30293231
Survival after biochemical failure in prostate cancer treated with radiotherapy: Spanish Registry of Prostate Cancer (RECAP) database outcomes.
González-San Segundo C, Jové J, Zapatero A, Pastor-Peidro J, Vázquez ML, Casaña M, Mengual JL, Gómez-Caamaño A, Gómez-Iturriaga A, Vallejo C, Henríquez I, Muñoz-García JL, Clemente J, Porras M, Collado E, Ossola G, Villafranca E, Cabeza MA, López-Torrecilla J. González-San Segundo C, et al. Among authors: henriquez i. Clin Transl Oncol. 2019 Aug;21(8):1044-1051. doi: 10.1007/s12094-018-02021-7. Epub 2019 Jan 7. Clin Transl Oncol. 2019. PMID: 30617939
Age, Gleason Score, and PSA are important prognostic factors for survival in metastatic castration-resistant prostate cancer. Results of The Uroncor Group (Uro-Oncological Tumors) of the Spanish Society of Radiation Oncology (SEOR).
Valero J, Peleteiro P, Henríquez I, Conde A, Piquer T, Lozano A, Soler CC, Muñoz J, Illescas A, Jove J, Flores MM, Baquedano J, Diezhandino P, de Celis RP, Pardo EH, Samper P, Villoslada I, Eguiguren M, Millan V. Valero J, et al. Among authors: henriquez i. Clin Transl Oncol. 2020 Aug;22(8):1378-1389. doi: 10.1007/s12094-019-02274-w. Epub 2020 Jan 27. Clin Transl Oncol. 2020. PMID: 31989474
50 results